Jilin Aodong Pharmaceutical Group Co., Ltd.

000623.SZ

000623.SZJilin Aodong Pharmaceutical Group Co., Ltd.

Shenzhen

12.74

CNY

-0.10

(-0.78%)

0.82EPS

15.54P/E

15.24BMarket Cap

Aug 30Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000719

Return %

Stock

S&P500

-24.17

26.76

-31.51

25.48

-23.02

87.24

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.99	1.24	1.68	1.93	2.01	2.38	2.56	2.86	2.66	1.94	2.02	2.53	3.06	2.91
Basic EPS, GAAP	1.71	0.55	0.91	1.22	2.23	1.45	1.6	0.8	1.21	1.48	1.56	1.57	1.3	0.83
Free Cash Flow per Basic Share	-0.3	-0.05	-0.09	-0.1	0.05	0.15	0.15	0.09	0.14	0.14	0.01	0.13	-0.31	-0.44
Dividend per Share	0.01	0.12	0.08	0.08	0.17	0.26	0.23	0.3	0.21	0.22	0.22	0.33	0.36	0.39
Book Value per Share	6.97	7.36	6.97	8.05	9.81	11.04	12.24	12.51	13.42	14.58	16	17.23	18.26	18.13
Tangible Book Value per Share	7.64	8.12	9.29	10.65	14.8	16.12	17.36	17.89	18.96	19.93	21.51	22.72	23.91	24.92
Basic Weighted Avg Shares	1,161	1,167	1,166	1,161	1,163	1,149	1,163	1,163	1,163	1,158	1,139	1,135	1,125	1,125
Sales/Revenue/Turnover	1,145	1,445	1,957	2,240	2,335	2,737	2,977	3,324	3,088	2,252	2,304	2,868	3,449	3,278
Operating Margin (%)	11.3	9.45	11.13	14.29	13.14	14.13	14.79	12.33	9.59	2.37	4.89	8.38	7.74	3.64
Depreciation Expense	71	83	95	107	135	161	179	187	194	195	204	226	234	- -
Net Income, GAAP	1,982	646	1,059	1,411	2,594	1,666	1,863	935	1,404	1,709	1,781	1,781	1,460	934
Effective Tax Rate (%)	19.45	4.79	10.8	4.54	2.56	4.84	4.55	6.5	5.84	1.46	- -	- -	3.72	4.88
Profit Margin (%)	173.07	44.72	54.11	62.97	111.09	60.89	62.6	28.13	45.45	75.89	77.29	62.09	42.33	28.5
Working Capital	1,308	1,450	1,895	2,178	1,282	2,157	2,107	5,143	5,322	4,782	4,870	3,767	1,277	2,595
LT Debt	23	- -	- -	22	22	- -	- -	1,910	2,006	2,144	2,235	2,321	21	1,016
Total Equity	9,095	9,753	11,100	12,659	17,584	18,874	20,514	21,244	22,445	23,529	25,039	26,338	27,500	28,624
Return on Invested Capital (%)	1.28	1.38	1.86	2.56	1.91	1.95	2.12	1.75	1.17	0.21	- -	- -	0.86	0.94
Return on Capital (%)	27.5	7.63	12.5	15.89	23.57	13.26	13.69	6.58	8.77	9.88	- -	- -	6.91	8.62
Return on Common Equity (%)	27.9	7.75	12.66	16.15	25	13.83	13.85	6.5	9.31	10.52	10.14	9.42	7.28	4.59

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	6.92%	2.58%	20.25%
Net Income, GAAP	10.14%	11.61%	-18.02%
Free Cash Flow	89.96%	171.76%	-329.88%
Total Cash Common Dividend	21.29%	5.68%	6.04%
Total Equity	9.9%	5.3%	4.41%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Shuqin Guo
Full Time Employees: 5,646
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 2158 Aodong Street Dunhua People's Republic of China 133700
IPO Date: Invalid Date
Website: www.jlaod.com
Business: Jilin Aodong Pharmaceutical Group Co., Ltd. produces and sells pharmaceutical products in China. The company offers various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It also engages in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; packaging design and printing activities; production and sale of medicinal packaging materials; and information consulting and advertising design activities. The company was founded in 1957 and is headquartered in Dunhua, China.

	Dec'23	Mar'24	Jun'24
ST Debt	3,011	1,687	1,140
LT Borrowings	- -	- -	994
LT Finance Leases	21	19	22
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,168	1,241	1,196
Market Capitalization	16,294	15,537	14,389

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.99	1.24	1.68	1.93	2.01	2.38	2.56	2.86	2.66	1.94	2.02	2.53	3.06	2.91
Basic EPS, GAAP	1.71	0.55	0.91	1.22	2.23	1.45	1.6	0.8	1.21	1.48	1.56	1.57	1.3	0.83
Free Cash Flow per Basic Share	-0.3	-0.05	-0.09	-0.1	0.05	0.15	0.15	0.09	0.14	0.14	0.01	0.13	-0.31	-0.44
Dividend per Share	0.01	0.12	0.08	0.08	0.17	0.26	0.23	0.3	0.21	0.22	0.22	0.33	0.36	0.39
Book Value per Share	6.97	7.36	6.97	8.05	9.81	11.04	12.24	12.51	13.42	14.58	16	17.23	18.26	18.13
Tangible Book Value per Share	7.64	8.12	9.29	10.65	14.8	16.12	17.36	17.89	18.96	19.93	21.51	22.72	23.91	24.92
Basic Weighted Avg Shares	1,161	1,167	1,166	1,161	1,163	1,149	1,163	1,163	1,163	1,158	1,139	1,135	1,125	1,125
Sales/Revenue/Turnover	1,145	1,445	1,957	2,240	2,335	2,737	2,977	3,324	3,088	2,252	2,304	2,868	3,449	3,278
Operating Margin (%)	11.3	9.45	11.13	14.29	13.14	14.13	14.79	12.33	9.59	2.37	4.89	8.38	7.74	3.64
Depreciation Expense	71	83	95	107	135	161	179	187	194	195	204	226	234	- -
Net Income, GAAP	1,982	646	1,059	1,411	2,594	1,666	1,863	935	1,404	1,709	1,781	1,781	1,460	934
Effective Tax Rate (%)	19.45	4.79	10.8	4.54	2.56	4.84	4.55	6.5	5.84	1.46	- -	- -	3.72	4.88
Profit Margin (%)	173.07	44.72	54.11	62.97	111.09	60.89	62.6	28.13	45.45	75.89	77.29	62.09	42.33	28.5
Working Capital	1,308	1,450	1,895	2,178	1,282	2,157	2,107	5,143	5,322	4,782	4,870	3,767	1,277	2,595
LT Debt	23	- -	- -	22	22	- -	- -	1,910	2,006	2,144	2,235	2,321	21	1,016
Total Equity	9,095	9,753	11,100	12,659	17,584	18,874	20,514	21,244	22,445	23,529	25,039	26,338	27,500	28,624
Return on Invested Capital (%)	1.28	1.38	1.86	2.56	1.91	1.95	2.12	1.75	1.17	0.21	- -	- -	0.86	0.94
Return on Capital (%)	27.5	7.63	12.5	15.89	23.57	13.26	13.69	6.58	8.77	9.88	- -	- -	6.91	8.62
Return on Common Equity (%)	27.9	7.75	12.66	16.15	25	13.83	13.85	6.5	9.31	10.52	10.14	9.42	7.28	4.59

	Dec'23	Mar'24	Jun'24
Total Current Assets	5,745	5,552	6,115
Accounts Receivable, Net	1,010	1,320	1,111
Cash, Cash Equivalents & STI	3,378	3,078	3,259
Inventories	872	889	972
Total Current Liabilities	4,468	3,472	3,520
Payables & Accruals	- -	- -	- -
ST Debt	3,011	1,687	1,140
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	637	613	663	955	2,868
2023	788	795	771	1,095	3,449
2024	861	550	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.02	- -	- -	- -	0.33
2023	0.04	- -	- -	- -	0.36
2024	0.06	- -	- -	- -	- -

Jilin Aodong Pharmaceutical Group Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year